The document outlines a significant advancement in the field of vaccinology with the development of a new live-attenuated respiratory syncytial virus (RSV) vaccine. This vaccine is distinguished by the deletion of the NS1 gene, which is hypothesized to enhance the immunogenic response by not antagonizing the body’s cellular mechanisms.
The technology under discussion represents a significant advancement in the field of virology and immunization. It involves a novel live-attenuated respiratory syncytial virus (RSV) vaccine that is genetically modified by deleting the NS2 gene, which is known to elicit cellular responses to viral infection, and by incorporating a stabilized I030s mutation in the L protein to improve its safety and efficacy.
The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a "DS2" version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides.
This technology includes a real-time RT-PCR (reverse transcriptase – polymerase chain reaction) Taqman assay using primers and probes specific for EV-D68 viral protein 1 nucleic acid. This assay provides a more specific identification of EV-D68 strains allowing better diagnosis. Human Enterovirus D68 (EV-D68) is a non-polio enterovirus that can cause mild to severe respiratory illness, especially in infants and children with asthma. The assay is simple, validated, and allows rapid testing and detection of EV-D68 in respiratory samples.
This technology includes Streptococcus pneumoniae isolates collected through CDC’s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.